Celgosivir is primarily investigated for its antiviral properties, particularly in the treatment of viral infections such as dengue fever and hepatitis C. It functions as an alpha-glucosidase inhibitor, which disrupts the viral replication process by interfering with the glycosylation of viral proteins. This mechanism makes it a potential candidate for reducing viral load and controlling the progression of these infections. Research is ongoing to evaluate its efficacy and safety in clinical settings, with a focus on its ability to enhance the immune response against viral pathogens. Additionally, its application in combination therapies is being explored to improve treatment outcomes for patients with resistant or chronic viral infections.